PriceTargets.com logo

Cellectar Biosciences - CLRB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 1,182.05%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.56 As of 11/20/2024 01:00 AM ET
▼ -0.05 (-3.11%)

This chart shows the closing price for CLRB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cellectar Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLRB

Analyst Price Target is $20.00
▲ +1,182.05% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cellectar Biosciences in the last 3 months. The average price target is $20.00, with a high forecast of $28.00 and a low forecast of $12.00. The average price target represents a 1,182.05% upside from the last price of $1.56.

This chart shows the closing price for CLRB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Cellectar Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024OppenheimerLower TargetOutperform ➝ Outperform$14.00 ➝ $12.00
10/11/2024OppenheimerReiterated RatingOutperform ➝ Outperform$14.00 ➝ $14.00
3/28/2024Roth MkmBoost TargetBuy ➝ Buy$20.00 ➝ $28.00
3/28/2024OppenheimerReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.00
3/4/2024Roth MkmReiterated RatingBuy ➝ Buy$20.00
5/5/2023OppenheimerLower Target$11.00 ➝ $10.00
11/15/2022Maxim GroupLower Target$7.00
11/8/2022Maxim GroupLower Target$12.50 ➝ $7.00
11/4/2022OppenheimerLower Target$47.00 ➝ $12.00
11/4/2022HC WainwrightBoost TargetBuy$3.00 ➝ $4.00
7/18/2022OppenheimerReiterated RatingOutperform$55.00
5/26/2022Maxim GroupLower Target$12.50
12/13/2021HC WainwrightReiterated RatingBuy$30.00
8/10/2021HC WainwrightReiterated RatingBuy$30.00
6/7/2021HC WainwrightReiterated RatingBuy$30.00
4/25/2021OppenheimerReiterated RatingBuy$55.00
3/2/2021Roth CapitalReiterated RatingBuy
8/11/2020HC WainwrightReiterated RatingBuy$30.00
7/1/2020OppenheimerInitiated CoverageOutperform$50.00
6/23/2020Maxim GroupInitiated CoverageBuy$30.00
3/10/2020HC WainwrightReiterated RatingBuy$30.00
1/21/2020Roth CapitalReiterated RatingBuy$100.00
12/10/2019HC WainwrightReiterated RatingBuy$30.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 5 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cellectar Biosciences logo
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $1.56
Low: $1.55
High: $1.69

50 Day Range

MA: $2.06
Low: $1.61
High: $2.20

52 Week Range

Now: $1.56
Low: $1.55
High: $4.45

Volume

742,656 shs

Average Volume

892,652 shs

Market Capitalization

$63.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectar Biosciences?

The following Wall Street analysts have issued reports on Cellectar Biosciences in the last year: Oppenheimer Holdings Inc., Roth Mkm, and StockNews.com.
View the latest analyst ratings for CLRB.

What is the current price target for Cellectar Biosciences?

0 Wall Street analysts have set twelve-month price targets for Cellectar Biosciences in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 1,182.1%. Roth Mkm has the highest price target set, predicting CLRB will reach $28.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $12.00 for Cellectar Biosciences in the next year.
View the latest price targets for CLRB.

What is the current consensus analyst rating for Cellectar Biosciences?

Cellectar Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLRB will outperform the market and that investors should add to their positions of Cellectar Biosciences.
View the latest ratings for CLRB.

What other companies compete with Cellectar Biosciences?

Other companies that are similar to Cellectar Biosciences include Ocuphire Pharma, Millendo Therapeutics, Fate Therapeutics, Atyr PHARMA and Benitec Biopharma. Learn More about companies similar to Cellectar Biosciences.

How do I contact Cellectar Biosciences' investor relations team?

Cellectar Biosciences' physical mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company's listed phone number is (608) 441-8120 and its investor relations email address is [email protected]. The official website for Cellectar Biosciences is www.cellectar.com. Learn More about contacing Cellectar Biosciences investor relations.